New Funds for Ultimovacs

Investors are recognizing the huge potential of Oslo Cancer Cluster member Ultimovacs. They are currently investing an additional 125 million NOK in the cancer research company.

 

Well known investors and Ultimovacs backers Stein Erik Hagen, Anders Wilhelmsen og Bjørn Rune Gjelsten are among financiers putting fresh money into the cancer research company, according to the Norwegian newspaper Finansavisen.

Preparing for the Stock Exchange
Kjetil Fjeldanger,  the Ultimovacs chairman, believes a stock exchange listing within 12-18 months is realistic. – We will start the preparations for a stock exchange listing to prepare for further financing, says Fjeldanger.

Ultimovacs has so far gathered a lot of funds. However, a lot of funding still remains because of the sheer cost of doing cancer research.

– Current funds will fund us until the start of phase two of clinical studies, explains General Manager of Ultimovacs, Øyvind Arnesen.

Fighting Cancer with the Body’s Own Tools
The company is developing a cancer vaccine that helps the body’s own immune system fight cancer. Currently, three concluded studies have been combined into one, and all participating patients will now be followed closely during a five year period to monitor their survival rate.

– The patients are doing well, but the documentation is not sufficient, but we continue in very good spirits, explains Arnesen.

However, a commercial vaccine will not be for sale until 2021, according to Arnesen.

Arnesen and Ultimovacs are also initiating a new study on melanoma cancer where the vaccine is used in combination with the most common immunotherapy remedies. The hope is that the two methods will strengthen each other and make an efficient cancer fighting remedy together. The study will conclude in 18 months.

Photocure with FDA Priority

Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview.

 

The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device system, wants to expand the labeling to include use for hospital patients not staying overnight.

Basically, a Priority Review  means that the FDA will speed up their approval process and a decision is now expected in the first half of 2018.

How Cysview Detects Cancer
Cysview is a method of detecting bladder cancer using photodynamic technology and is the only FDA approved product for use with blue light cystoscopy, where a device called a cystoscope is used to detect cancer inside the bladder.

Cysview is injected into the bladder through a catheter. It accumulates differentially in malignant cells. When illuminated with blue light from the cystoscope, the cancerous lesions fluoresce red, highlighting the malignant areas.

An important Tool
— Photocure is dedicated to improving the lives of patients with bladder cancer and we are committed to working with the FDA to bring this important clinical tool to the US market as soon as possible.

— We look forward to hearing a decision from the FDA early next year on the US Cysview® label expansion to include patients undergoing surveillance cystoscopy using a flexible scope, said Kjetil Hestdal, President & CEO, Photocure ASA.

 

 

 

About Photocure:

Photocure, the world leader in photodynamic technology, is a Norwegian based specialty pharmaceutical company. They develop and commercialize highly selective and effective solutions in several disease areas such as bladder cancer, HPV and precancerous lesions of the cervix and acne.

Their aim is to improve patient care and quality of life by making solutions based on Photocure Technology™ accessible to patients worldwide.

Photocure was founded by the Norwegian Radium Hospital in 1997. Today, the company, headquartered in Oslo, Norway, has over 60 highly skilled employees and operates in Norway, Sweden, Denmark, Finland and the United States.

Targovax Releases Positive Clinical Results

Targovax has received very positive results regarding the survival rate of patients with pancreatic cancer.

Immune-oncology aims to help the body’s own immune system fight cancer and the ambition is to address the unmet need for long-term survival for patients with advanced cancers.

13 of 13
The company specializes in immune-oncology and is a member of Oslo Cancer Cluster. It recently released information revealing that 13 of 13 test subjects where alive after one year of treatment in a stage two clinical trial study. In addition, an active immune response–meaning the immune system was triggered to attack the cancer–was observed in as much as 11 of 13 patients.

No allergic reactions
These results came after the number of test subjects were reduced from 19 to 13 to see if allergic reactions stalled with reduced dosages of the TG01; Targovax’s lead RAS immunotherapy product. And luckily, no serious allergic reactions were observed,

Magnus  Jäderberg MD, Chief Medical Officer of Targovax, said:

– We are delighted that we maintain a strong immune response and one-year survival rate with the reduced dosing  regimen, essentially  equivalent  to  and  consistent with the previously  reported data  from the  main cohort.

These new results are so positive that stock market analysts DnB Markeds predict a serious stock market rise for Targovax.

 

About Targovax

Arming the patient’s immune system to fight cancer

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

In July, 2016 the Company listed its shares on Oslo Axess.

Read more

 

Curida’s Spreading Roots

Curida has come a long way from defending their place at the Norwegian factory to setting their sights internationally. What is Curida and their goal all about?

 

Creating value within ones own country while steadily spreading roots globally is no easy feat, but the young Norwegian pharmaceutical company Curida is blooming.


Overcoming the threat at Elverum

The company’s history is a classic tragedy intertwined with devotion and a feel-good ending. In 2013, change of ownership and new strategic priorities threatened to strip 190 employees from their jobs at the manufacturing site in Elverum, Norway. New owners Takeda announced that the site in Elverum was to be shut down, after providing pharmaceutical manufacturing since 1974.

What followed was a feat of patience and outstanding motivation. Employees and management joined forces to establish a new company, form a new business model, and get going. In July 2015, Curida was established and operation carried on.


Going abroad 

Oslo Cancer Cluster member Curida is now a Contract Development and Manufacturing Organization, offering expertise in manufacturing and development of liquid pharmaceuticals.

The Curida customer base ranged from early-phase biotech companies to large, multinational pharma companies. Further growth in the international market is a top priority for the company. Curida is specialized on liquid products, using for example the advanced blow-fill-seal technology.

 

Unstoppable Ambition
Naturally, Curida has ambitious goals for home as well.

– In Norway we work closely with other start-up companies and make sure to help them thrive in production and innovation. Regardless of our vision to be a top-competitor internationally, locally, in Norway, we strive to become a national centre for industrialisation of medical innovation, says CEO Leif Rune Skymoen.

After overcoming the potential reality of shutting down, Curida now bursts through with unstoppable energy and ambition.

Young Skills at Thermo Fischer

The innovation company of the year wants to encourage young talents. 

 

Six students from Ullern Upper Secondary School spent their school day at Thermo Fisher Scientific just days after the company won the prestigious award as the innovation company of the year in Norway.

As part of the school collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster, Thermo Fisher Scientific opens their labs for science students at work deployment.

 

Curious about the school collaboration? Check out our new webpage!

The Dynabeads
The students got a unique insight into how one of Norway’s largest biotechnology companies advances their products, based on the so-called Ugelstad-beads or Dynabeads, developed by Professor John Ugelstad in the late 1970s.

Today, Dynabeads are further industrialized for use in specialized diagnostic tests and cancer treatments worldwide. Annually, the beads are used in an estimated number of four billion diagnostic analyses.

Scientist Synne Larsen and three students are in the company laboratory in Lillestrøm, a ten minute train ride from the capital, where Thermo Fisher Scientific quality checks its products in Norway.

Impressed students 
– I find it incredibly useful to see how our learning at school is being used in the workplace, says student Emma E. J. Botten.

Together with two co-students she was able to see the research and production done in the company’s facilities in Lillestrøm. In parallel, three of the girls’ fellow students were in Oslo and tried out life as crime scene investigators, using Dynabeads as a tool for finding DNA, in the company’s facilities in Montebello.

– It’s impressive to see how much work lies behind their products and how dedicated those who work here are, says student Nora B. Grone.

Diverse employment strategy
The students are in their third year at Ullern Upper Secondary School, with science as their speciality. They all want a career in medicine, global health, mathematics, physics or engineering. A tour of the lab and a visit to the factory were therefore among the highlights of the day.

– It was a bit overwhelming to see Ugelstad’s equation, which is the recipe for the beads, says student Thilde E. Kjorstad.

– Yes, but keep in mind that everyone cannot be as brilliant as Ugelstad. Everybody we employ is equally important and we must have people with different backgrounds and experience, says Erlend Ragnhildstveit, Research Director of Thermo Fisher Scientific in Norway.

Useful cooperation
Thermo Fisher Scientific is a member of Oslo Cancer Cluster. Part of the staff is situated in Oslo Cancer Cluster Innovation Park, where Ullern Upper Secondary School is located as well.

– The collaboration with Ullern is useful and important to us as a company. This makes it easier to host deployments. In order to develop our business further, as well as the health industry in Norway, we need people with a science background, says Erlend Ragnhildstveit.

Photocure’s Promising Combo

Photocure reveals promising results in bladder cancer through the use of Blue Light Cytoscopy alongside the drug Hexvix. 

Bladder cancer endangers 167,000 people in Europe annually followed by over 59,000 deaths.

Men are especially at risk, where a staggering 75% of bladder cancer cases occur. Not only that, but bladder cancer has a reputation as being one of the most expensive cancers to have, due to its high reccurence rate with an average of 61% reccurence the first year followed by 78% for the next five years.

The results we needed
As such, there is an increasingly urgent need to develop better methods of both managing and diagnosing the disease. We’re already hearing positive news from the Norwegian company Photocure; a leader in photodynamic technology. Photocure revealed the results from their study on the 18th of August, where the results appear promising in terms of prognosis and diagnosis.

The promising new combo
By combining Blue Light Cystoscopy (BLC) and Hexvix, Blue Light Cytoscopy being the insertion of a tube in the urinary tract instilled with a photosensitizing agent, they found the overall reccurence rate of three years had decreased substantially. More specifically, by combining Blue Light Cytoscopy with Hexvix, they found that the recurrence rate dropped down to 39% for the next three years, as opposed to using an optimized White Light Cytoscopy (WLC), a standard cytoscopy, that resulted in a 53.3% of reccurence.

Substantially better
The benefit was even more substantial for those with high-risk disease, where the chances of recurrence at year three were 52.1% for the Blue Light Cytoscopy combo as opposed to the White Light Cytoscopy, found to be at around 80%.

How does it work?
The probable reasoning for this improvement lies in how the new combo works to detect bladder cancer. By using Blue Light Cytoscopy with Hexvix, which is a drug that is selectively taken up by cancer cells in the bladder, they are able to see the cancer light up in bright pink. This enables the doctors  to accurately resect and make better management deciscions, thusly improving the patients outlook and way of life.

Roche Medicine Ready to Fight Breast Cancer

On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway.

The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, a protein which promotes growth of cancer cells.

About 15-20% of cases in breast cancer, cancer cells have a gene mutation that produces excess HER2 protein, thusly making it a more aggressive form of breast cancer as well as being resistant to hormone therapy. However, treatments that specifically target HER2 are very effective.

New Drug Kadycla
This is where newly developed drug Kadycla comes in.

Kadycla is the first medicine targeted towards breast cancer patients where the cell lymph nodes are linked to the targeted antibody; meaning it’s the first drug where lymph nodes, or parts of the cell that filter out cancer, are linked to the antibody that attacks or even neutralizes the infected cell. This causes the chemo to target the HER2 positive cancer cells.

Prolonged Survival Rate
With the drugs approval, around one hundred Norwegian cancer patients are provided with a treatment program that shows a median prolonged survival rate of 5,8 months, compared to the combination of lapatinib and kapecitabine for persons with the variant HER2-positive breast cancer.

Better Quality of Life
On top of this, it’s known that spreading breast cancer is a deadly disease with lower quality of life, but Kadycla helps by attacking cancer cells in place of the body’s own healthy cells. Essentially, this means better quality of life for the patient due to fewer symptoms brought on by the disease.

Reached an Agreeable Solution
Kadycla, since September in 2014, has been recommended in the Norwegian Breast Cancer Group’s medical guidelines for those who would benefit from its capabilities. Roche, in this case, through the span of three years aligned eight different pricing options for the authorities. In regards to this, Audun Ohna, director of market access and pricing, comments:

– We have worked a long time so that Norwegian breast cancer patients can have the chance to use Kadycla in Norwegian health services. After roughly three years negotiating, where we have stretched ourselves thin both economically and in variating payment solutions, we can finally and gladly say we have reached a solution that is both acceptable for both parties. This will benefit patients, doctors and society as a whole.

Meet Our New Members – Part Two

We are proud to introduce Oslo Cancer Cluster’s new members. This is the second part of two stories about our new members.

You can find the first part HERE.

On the 24th of August, Oslo Cancer Cluster hosted a bustling summer party in the Oslo Cancer Cluster Incubator, where the new members had the chance to introduce their amazing work.

This is a brief introduction to those of the new members who primarily work in consulting.

Dehns
At Dehns, they have a commercially focused and practical approach to intellectual property that helps them to turn inspired thinking into patents, registered designs and trade marks. Dehns was founded in 1920 and has over 90 staff members, with offices in multiple locations across England. Dehns is one of the largest firms of trade mark and patent attorneys in Europe.

– Partnering with Oslo Cancer Cluster will allow us at Dehns to have more contact with the diverse members at Oslo Cancer Cluster that could benefit from our services. Norway is a buzzing place for opportunity, so we believe this is a special chance to be more present. By doing this, we hope to help companies with whatever questions or problems they might have, whilst also setting sights on getting in contact earlier, so that we can get to the root of the problem quicker and make a real impact as a result. Undoubtedly, getting to the root of the problem at the start is more exciting for everyone, and we aim to do just that, says Barbara Rigby, associate at Dehns.

GIAMAG
GIAMAG was established in 2012 as a commercial spin-off of Norway’s Institute for Energy Technology (IFE), where their patented technology is based off of the Institute’s research. GIAMAG is not wholly belonging to the area of consulting, but nonetheless offers consulting services in their product: one of the world’s most forceful and configurable magnets. GIAMAG’s mission is to provide solutions based on magnet technology for a varying range of industrial applications. They have the expertise to design and configure magnet systems to customer’s specific requirements.

Acapo
Acapo is an Intellectual Property Rights (IPR) firm mainly focused on the maintanace of patents, trademark registrations and design. Acapo, despite being located in several places, works as one company. The head office is located in Bergen. Acapo has a joint administration with one legal and one patent department. They strive for the highest degree of both service and quality, where the most important assets are their highly qualified professionals and staff members. They do not only offer advice in areas related to Intellectual Property, but also in business areas. Acapo covers all technical fields.

Artemida
Artemida Pharma is a consultancy company in drug development who has highly experienced scientists representing multiple disciplines and therapeutic areas. Artemida Pharma offers optimised strategic drug development for biotechnology and pharmaceutic clients. They have past experience with a wide variety of clients, geographic areas and product types that enable them to offer integrared project-driven solutions.

DNV GL
DNV GL allows organizations to progress the sustainability and safety of their business. They provide classification, technical assurance, software and independent expert advisory services to the maritime, oil & gas and energy industries. They also provide certification services to customers across a wide range of industries. In terms of healthcare, they support organizations in this sector across the globe by applying system thinking to address risks and deliver high-quality, person centered care.

IRW Consulting
IRW is a Nordic Contract Research Organization (CRO) With more than fifteen years of experience in conducting clinical trials, non-interventional studies and medical device studies. They have built a wide network in Scandinavia as well as with the rest of Europe and the United States. IRW, depending on the customer’s requirements, is equipped with staff that is either outsourced or works with in-house projects. They cover all stages of clinical development.

Meet our new members – Part One

We are proud to introduce Oslo Cancer Cluster’s new members. This is the first part of two stories about our new members.

You can find the second part HERE.

On the 24th of August, Oslo Cancer Cluster hosted a summer party with the intention of getting to know their newest members in an informative and fun setting. The party started with a heartfelt welcome and speech held by Oslo Cancer Cluster’s General Manager Ketil Widerberg and intensive mingling amongst guests. After the welcome was in order, each member stood up, in turn, to introduce their amazing work.

Of the 14 new members we have so far this year, here’s an introduction to those who primarily work in the area of biotechnology.

Precision Oncology
Precision Oncology is a specialty contract research organization (CRO) that provides clinical research services. The company primarily provides application of metrics-driven project management to perfect oncology drug development.

As for their inspiration and reasoning for joining the Oslo Cancer Cluster roster of members, Andrea Cotton-Berry, head of Strategic operations at Precision Oncology, responds:

– What really inspires us at Precision Oncology, is matching the right drug to the right patient, by using biomarkers for patient identification and stratification; a true personalized medicine approach, to find more efficient treatments for patients with advanced cancers. We are looking forward to bringing our team of oncology development experts to contribute to the Oslo Cancer Cluster mission and initiatives, especially advancing immuno-oncology research.

Personalis
Personalis is a leading preciscion medicine company focused on advancing next generation sequencing based services for immuno-oncology. The company is mainly focused on producing the most accurate genetic sequence from each sample set, and using analytics and privately owned content to draw reliable and accurate biomedical interpretations of the data.

In regards to current and future inspiration, Erin Newburn, Senior Manager and Field Applications Scientist at Personalis, comments:

– We aspire to utilize next-generation sequencing as a multi-dimensional platform for bio-marker discovery across cancer therapeutics, as well as throughout developmental stages.

iNANOD
iNANOD is a nanotechnology based anti-cancer drug developing company established in 2016. Their goal is to increase efficacy of anti-cancer drugs and to reduce side-effects for cancer patients as well as maximizing the patients longevity. They aim to become a pharmaceutical company for anti-cancer nanomedicines in the near future.

As for expectations and reasoning for joining Oslo Cancer Cluster, Nalinava Sengupta, CEO and Co-Founder of iNANOD shares his view:

– We think our project – to develop cancer nano-medicine – fits best with Oslo Cancer Cluster. In the incubator we get in touch with other similar firms who have achieved milestones in cancer drug delivery. We expect synergistic knowledge transfer within the incubator network, as well as various kinds of help from the cancer research related entrepreneurial ecosystem developed at Oslo Cancer Cluster. This also helps with business developmental aspects and project application writing.

Norgenotech
Norgenotech is a start-up company that originated from the EU project COMICS that aimed at improving production methods for analysis of DNA damage and repair. Norgenotech mainly assesses genotoxicity, or property of chemical agents that damage the genetic information within a cell, as well as drugs. The company also participates in research projects and developing tools for measuring DNA integrity in patients.

Eisai
Eisai AB originates from a global company in Japan that is active in the manufacturing and marketing of pharmaceutical drugs, pharmaceutical production systems, and over-the-counter drugs. Eisai AB, that will be joining the Oslo Cancer Cluster roster of members, is the sales subsidiary of Eisai Company.

Immunitrack
Immunitrack is a startup company with capabilities in production and studies of protein molecules central to the adaptive immune system in humans in order to develop new therapeutics. Their mission is to provide the research community with tools to redesign or select drug candidates at the early stage of research and development, but also to provide reagents to monitor leading drug candidates effect on patient’s immune system.

Nacamed
Nacamed‘s goal is to produce nanoparticles of silicon material for targeted drug delivery of chemotherapy, radiation therapy and diagnostics to kill cancer cells. By using silicon nanoparticles in cases such as therapy, the particles are biodegradable which entails a clean delivery without any side-effects as they completely disappear and dissolve from the body.

Arctic Pharma
Arctic Pharma is a privately held startup biotech company founded in 2012 that primarily focuses on developing innovative anti-cancer drugs. They do this by exploiting cancer cells and their peculiar features, or more specifically, by targeting key enzymes that are upregulated, or have been increased in terms of stimulus with inhibitors designed at Arctic Pharma. Essentially, their main mission is to become a leader in designing cancer therapies that are both environmentally friendly and have few side effects.

Thermo Fisher Scientific Wins Innovation Award

The Research Council of Norway has given Thermo Fisher Scientific the prestigious Innovation Award for their Dynabeads.

 

The Oslo Cancer Cluster member Thermo Fischer Scientific was awarded the prize for developing an entirely new variant of an existing product, making it possible to analyse human genes quickly and effectively and improve diagnostic testing and patient treatment.

This is the technology known as «Dynabeads» that makes faster and cheaper DNA-sequencing accesible.

– The award means a lot to us as a company, and to everybody who has been working on product, production and launch during these years. It is an acknowledgement that investment, cooperation and important global products are noticed, says Ole Dahlberg, CEO at Thermo Fischer Scientific Norway.

Vital role in Norwegian biotech
Thermo Fisher Scientific is one of Norway´s leading biotechs and among the most profitable. The company has played a vital role in Norwegian biotech with the development of «Dynabeads», used all over the world to separate, isolate and manipulate biological materials.

Thermo Fisher’s Dynabeads are used in basic research, in billions of diagnostic tests, as well as in immunotherapy.

In May this year, Thermo Fisher Scientific was nominated for the “Norway’s smartest industrial company” award for the same technology. The smart element was using the beads in a completely new way on a microchip in combination with semiconductor technology. This link between biotech and electronics has created the instruments from Thermo Fisher which we now see in research institutes and diagnostic labs all over the world.

Ambitious research and development
– Thermo Fisher Scientific is carrying out an ambitious research and development effort in a very important area. The company is achieving this by using its own resources, seeking cooperation with exacting customers and drawing on public funding schemes from, among others, the Research Council of Norway. In this way, the company contributes to job creation as well as value creation, said Monica Mæland, Minister of Trade and Industry, according to The Research Council of Norway. She presented the Innovation Award during the Arendal Week in August.

The Research Council’s Innovation Award comprises a cash prize of NOK 500 000 and is given each year to a business or public entity that has demonstrated an outstanding ability to apply research results to create research-based innovation.